These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 8378599)

  • 1. Monocytes and macrophages in cancer immunotherapy.
    Bartholeyns J
    Res Immunol; 1993 May; 144(4):288-91; discussion 294-8. PubMed ID: 8378599
    [No Abstract]   [Full Text] [Related]  

  • 2. Adoptive immunotherapy of solid tumors with activated macrophages: experimental and clinical results.
    Bartholeyns J; Lopez M; Andreesen R
    Anticancer Res; 1991; 11(3):1201-4. PubMed ID: 1888150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives.
    Andreesen R; Hennemann B; Krause SW
    J Leukoc Biol; 1998 Oct; 64(4):419-26. PubMed ID: 9766621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon gamma and lipopolysaccharide.
    Hennemann B; Beckmann G; Eichelmann A; Rehm A; Andreesen R
    Cancer Immunol Immunother; 1998 Jan; 45(5):250-6. PubMed ID: 9439648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new approach to adoptive immunotherapy of cancer using tumorcytotoxic macrophages grown from peripheral blood monocytes.
    Andreesen R; Scheibenbogen C; Brugger W; Krause S; Leser HG; Kopf S; Engler H; Schümichen C; Löhr GW
    Cancer Detect Prev; 1991; 15(5):413-21. PubMed ID: 1751953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 111In-oxine labelling of tumour-cytotoxic macrophages generated in vitro from circulating blood monocytes: an in vitro evaluation.
    Marienhagen J; Hennemann B; Andreesen R; Eilles C
    Nucl Med Commun; 1995 May; 16(5):357-61. PubMed ID: 7659388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune regulation by monocytes.
    Murray PJ
    Semin Immunol; 2018 Feb; 35():12-18. PubMed ID: 29290545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy.
    Sznol M; Urba WJ
    Cancer Chemother Biol Response Modif; 1993; 14():227-48. PubMed ID: 8312104
    [No Abstract]   [Full Text] [Related]  

  • 9. Activated killer monocytes: preclinical model systems.
    Shinomiya H; Shinomiya M; Stevenson GW; Stevenson HC
    Immunol Ser; 1989; 48():101-26. PubMed ID: 2488316
    [No Abstract]   [Full Text] [Related]  

  • 10. Large-scale production of human tumorcytotoxic macrophages grown from blood monocytes of cancer patients.
    Brugger W; Scheibenbogen C; Krause S; Andreesen R
    Cancer Detect Prev; 1991; 15(5):407-12. PubMed ID: 1751952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive cellular immunotherapy of cancer: future perspectives.
    Stevenson HC
    Immunol Ser; 1989; 48():229-36. PubMed ID: 2488324
    [No Abstract]   [Full Text] [Related]  

  • 12. Adoptive immunotherapy with activated macrophages grown in vitro from blood monocytes in cancer patients: a pilot study.
    Lopez M; Fechtenbaum J; David B; Martinache C; Chokri M; Canepa S; De Gramont A; Louvet C; Gorin I; Mortel O
    J Immunother (1991); 1992 Apr; 11(3):209-17. PubMed ID: 1515425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical/technical challenges in adoptive cellular immunotherapy: in vitro culture techniques.
    Yannelli JR; Jadus MR; Beckner S; Lacerna LV; Oldham RK
    Immunol Ser; 1989; 48():191-206. PubMed ID: 2488322
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase I/II trial of autologous activated macrophages in advanced colorectal cancer.
    Eymard JC; Lopez M; Cattan A; Bouché O; Adjizian JC; Bernard J
    Eur J Cancer; 1996 Oct; 32A(11):1905-11. PubMed ID: 8943673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune therapy with macrophages: present status and critical requirements for implementation.
    Bartoleyns J; Romet-Lemonne JL; Chokri M; Lopez M
    Immunobiology; 1996 Oct; 195(4-5):550-62. PubMed ID: 8933156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-cytolytic human macrophages cultured as nonadherent cells: potential for the adoptive immunotherapy of cancer.
    Helinski EH; Hurley EL; Streck RJ; Bielat KL; Pauly JL
    Cancer Detect Prev; 1990; 14(4):471-81. PubMed ID: 2224910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy.
    Andreesen R; Scheibenbogen C; Brugger W; Krause S; Meerpohl HG; Leser HG; Engler H; Löhr GW
    Cancer Res; 1990 Dec; 50(23):7450-6. PubMed ID: 1701343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
    Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
    Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy with autologous macrophages: current status and future perspectives.
    Andreesen R; Hennemann B
    Pathobiology; 1991; 59(4):259-63. PubMed ID: 1883523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated killer monocytes: use in clinical trials.
    Lacerna LV; Sugarbaker PH; Stevenson HC
    Immunol Ser; 1989; 48():127-38. PubMed ID: 2488317
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.